相似文献
1
Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status.
Br J Cancer. 2003 Nov 3;89(9):1661-3. doi: 10.1038/sj.bjc.6601293.
2
Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications.
Clin Oncol (R Coll Radiol). 2016 Jan;28(1):1-3. doi: 10.1016/j.clon.2015.10.005. Epub 2015 Nov 6.
3
Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis.
Am J Epidemiol. 1997 Aug 15;146(4):307-14. doi: 10.1093/oxfordjournals.aje.a009271.
4
Frequency of distribution of oestrogen and progesterone receptors positivities in breast cancer cases in Benin-City, Nigeria.
Niger Postgrad Med J. 2012 Mar;19(1):19-24.
5
Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status.
J Clin Pathol. 1996 Nov;49(11):920-5. doi: 10.1136/jcp.49.11.920.
6
Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.
7
p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas.
Cytopathology. 2001 Jun;12(3):197-202. doi: 10.1046/j.1365-2303.2001.00315.x.
8
The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?
J Clin Pathol. 2009 Jan;62(1):95-6. doi: 10.1136/jcp.2008.060723.
9
Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
Eur J Cancer. 2014 Mar;50(5):1035-7. doi: 10.1016/j.ejca.2014.01.013. Epub 2014 Jan 31.
10
Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status.
Genet Epidemiol. 1996;13(2):207-21. doi: 10.1002/(SICI)1098-2272(1996)13:2<207::AID-GEPI6>3.0.CO;2-4.
引用本文的文献
1
Oral Contraceptive Use and Assessment of Breast Cancer Risk among Premenopausal Women via Molecular Characteristics: Systematic Review with Meta-Analysis.
Int J Environ Res Public Health. 2022 Nov 21;19(22):15363. doi: 10.3390/ijerph192215363.
2
Oncobiology and treatment of breast cancer in young women.
Cancer Metastasis Rev. 2022 Sep;41(3):749-770. doi: 10.1007/s10555-022-10034-6. Epub 2022 Apr 30.
3
Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes Status: A Systematic Review and Meta-Analysis of Case-Control Studies.
Cancers (Basel). 2022 Jan 23;14(3):574. doi: 10.3390/cancers14030574.
4
A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women's lifestyle and health cohort.
BMC Cancer. 2019 Aug 14;19(1):807. doi: 10.1186/s12885-019-5985-6.
5
Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.
Int J Cancer. 2019 Dec 15;145(12):3207-3217. doi: 10.1002/ijc.32214. Epub 2019 Mar 5.
6
Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
PLoS One. 2018 Nov 7;13(11):e0205034. doi: 10.1371/journal.pone.0205034. eCollection 2018.
7
Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study.
Int J Cancer. 2018 Jun 1;142(11):2293-2302. doi: 10.1002/ijc.31266. Epub 2018 Feb 7.
8
Differential Patterns of Risk Factors for Early-Onset Breast Cancer by ER Status in African American Women.
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):270-277. doi: 10.1158/1055-9965.EPI-16-0692. Epub 2016 Oct 18.
9
FGFR2 gene polymorphisms are associated with breast cancer risk in the Han Chinese population.
Am J Cancer Res. 2015 Apr 15;5(5):1854-61. eCollection 2015.
10
Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women.
Springerplus. 2014 Dec 11;3:727. doi: 10.1186/2193-1801-3-727. eCollection 2014.
本文引用的文献
1
Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.
J Natl Cancer Inst. 2003 Mar 19;95(6):448-57. doi: 10.1093/jnci/95.6.448.
2
Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age.
Am J Epidemiol. 2002 Sep 15;156(6):507-16. doi: 10.1093/aje/kwf065.
3
Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
J Clin Oncol. 2000 Nov 1;18(21 Suppl):107S-12S.
4
Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS).
J Natl Cancer Inst Monogr. 1999(26):95-100. doi: 10.1093/oxfordjournals.jncimonographs.a024232.
5
Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.
Am J Epidemiol. 2000 Apr 1;151(7):703-14. doi: 10.1093/oxfordjournals.aje.a010265.
6
The shape of age-incidence curves of female breast cancer by hormone-receptor status.
Cancer Causes Control. 1999 Oct;10(5):431-7. doi: 10.1023/a:1008970121595.
7
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Cancer Res. 1999 Apr 15;59(8):2011-7.
8
Breast cancer in Australian women under the age of 40.
Cancer Causes Control. 1998 Mar;9(2):189-98. doi: 10.1023/a:1008886328352.
9
Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?
Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):319-26.
10
Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance.
Acta Oncol. 1988;27(1):1-19. doi: 10.3109/02841868809090312.
Zotero 插件